MedTrace Logo

Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)

NCT04490837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3500

Last updated 2021-07-29

No results posted yet for this study

Summary

Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.

Conditions

Interventions

DIAGNOSTIC_TEST

ELISA and Rapid test to detect antibodies against COVID-19

Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2020-07-31
Completion
2020-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490837 on ClinicalTrials.gov